ALTB-268

Therapeutic Area Indication

Therapeutic Area

Product Overview
Inheriting the unique mechanism of action from ALTB-168, ALTB-268 is subtly designed as a tetravalent molecule to achieve better efficacy. From preclinical and phase 1 clinical studies ALTB-268 exhibits not only comparable safety profiles, but also improved potency in down-regulating chronic pathogenic T cells. Therefore, a lower dosage to obtain an equivalent efficacy in clinical is expected.

Indication

Ulcerative Colitis TBA

Ulcerative Colitis

1

  • PRECLINICAL

  • PHASE I

  • PHASE IIA

    Phase II

  • PHASE IIB

  • PHASE III

Introduction

Ulcerative colitis (UC), characterized by the hallmark clinical symptoms of bloody diarrhea, rectal urgency, and tenesmus, is a chronic inflammatory disease affecting the colorectal mucosa. The underlying pathogenesis of UC is complex, and accumulating evidence suggests that environmental factors contribute to triggering an overly active or dysregulated T-cell mediated immune-inflammatory response in genetically predisposed individuals, which eventually leads to mucosa damage.

Based on the structure of ALTB-168, we have developed ALTB-268, a second-generation antibody with tetravalent design, which has demonstrated improved potency in a pre-clinical setting. These preclinical studies with ALTB-268 have demonstrated an ability to downregulate T-cells at significantly lower drug concentrations as compared with ALTB-168 across various relevant assays measuring T-cell activation, proliferation and cytokine secretion.

The company is dedicated to bringing forth ALTB-268 into the clinic, currently in a Phase 2a trial with ulcerative colitis patients. Additional autoimmune indications will be explored based on solid signs of clinical efficacy demonstrated with ALTB-168.

More

TBA

2

  • PRECLINICAL

  • PHASE I

    Phase I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

Introduction

With the promising phase 2a results of ALTB-168 and the pre-clinical research in multiple Immunological and Inflammatory (I&I) diseases, indication expansion of ALTB-268 is under planning.